Biotech

La Jolla Pharmaceutical (Nasdaq:LJPC) today announced that GIAPREZA™ (angiotensin II), injection for intravenous infusion, is now commercially available. In December 2017, GIAPREZA was approved by the U.S. Food and Drug Administration (FDA) to increase blood pressure in adults with septic or other distributive shock. As quoted in the press release: GIAPREZA mimics the body’s endogenous regulatory peptide that is …

La Jolla Pharmaceutical (Nasdaq:LJPC) today announced that GIAPREZA™ (angiotensin II), injection for intravenous infusion, is now commercially available. In December 2017, GIAPREZA was approved by the U.S. Food and Drug Administration (FDA) to increase blood pressure in adults with septic or other distributive shock.

As quoted in the press release:

GIAPREZA mimics the body’s endogenous regulatory peptide that is central to the renin-angiotensin-aldosterone system to increase blood pressure. GIAPREZA is available in 1 mL single-dose vials, each containing 2.5 mg of angiotensin II (as a sterile liquid).

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20437.04+150.84
TSXV700.05-0.61
DOW32217.80+289.18
S&P 5003994.27+52.79
NASD11490.91+226.46
ASX7128.80-20.10

COMMODITIES

Commodities
Gold1854.59-12.71
Silver22.04-0.09
Copper4.28-0.02
Palladium2013.65+16.65
Platinum950.15-5.84
Oil110.74+0.97
Heating Oil3.75+0.10
Natural Gas8.88+0.09

DOWNLOAD FREE REPORTS

×